Pathos AI Raises $365M Series D, Reaching $1.6B Valuation

Pathos AI, a biotech startup leveraging artificial intelligence to accelerate oncology drug development, has raised $365 million in a Series D funding round, bringing its valuation to approximately $1.6 billion. The company plans to use the proceeds to advance its clinical-stage pipeline, including trials for cancer drugs licensed from Novo Nordisk and Prelude Therapeutics, and to further develop its AI-powered platform, which integrates multimodal clinical, molecular, and imaging data to improve clinical trial design, biomarker discovery, and therapeutic innovation. Pathos recently partnered with Tempus and AstraZeneca to develop the largest multimodal foundation model in oncology, combining data and AI expertise to enhance drug development precision and speed. The company’s AI platform, PathOS, aims to simplify complex oncology data analysis, supporting the identification of biomarkers and better patient stratification for clinical trials. Under new CEO Iker Huerga, formerly of AstraZeneca and Tempus, Pathos is focused on transforming drug development by harnessing AI to bring effective therapies to patients more rapidly. This funding marks a significant milestone for Pathos as it continues to pioneer an AI-driven approach to cancer drug discovery and clinical execution.